TrialThe Journal of dermatology2017

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).

Hidehisa Saeki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.